Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carmelo Nucera, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Carmelo Nucera and Peter Sadow.
Connection Strength

2.464
  1. Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocr Relat Cancer. 2015 Dec; 22(6):L23-8.
    View in: PubMed
    Score: 0.642
  2. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.584
  3. Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2020; 11:596223.
    View in: PubMed
    Score: 0.225
  4. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFß1 Axis. Clin Cancer Res. 2018 12 01; 24(23):6078-6097.
    View in: PubMed
    Score: 0.193
  5. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015 Dec 15; 6(40):42445-67.
    View in: PubMed
    Score: 0.161
  6. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett. 2016 10 01; 380(2):577-585.
    View in: PubMed
    Score: 0.156
  7. Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. Discoveries (Craiova). 2015 Apr-Jun; 3(2).
    View in: PubMed
    Score: 0.153
  8. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2013; 4:189.
    View in: PubMed
    Score: 0.140
  9. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16(3):296-309.
    View in: PubMed
    Score: 0.115
  10. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer. 2012 Oct; 19(5):695-710.
    View in: PubMed
    Score: 0.032
  11. SCF(ß-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012 Jul 02; 209(7):1289-307.
    View in: PubMed
    Score: 0.032
  12. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012 Feb; 153(2):985-94.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.